Hollis-Eden cuts 33% of staff to weather crisis

9 February 2009

In light of the economic downturn, USA-based Hollis-Eden Pharmaceuticals has implemented an aggressive cost-cutting plan in order to preserve  capital.

The firm is to focus its resources on advancing the Triolex (HE3286) and  Apoptone (HE3235) development programs. To achieve this, Hollis-Eden  will reduce its workforce by around 33%, or 20 employees, as well as  freeze salaries and suspend bonuses for all remaining staff, including  executive officers. The firm believes that, as it had no outstanding  debts, this will allow it to operate without reliance on equity markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight